Panel: Leadership Strategies to Survive and Excel in a Post-COVID World

  • What are some of the unexpected lessons —good and bad— we have taken away from 2020 and 2021?
  • Discussing examples of innovations created by necessity during the global pandemic that will continue on long into the future
  • Taking this chapter in our working lives as an opportunity to re-evaluate, reconsider, and rethink some of the processes and strategies we had in place before COVID-19
  • How should we adjust our approach to communication, coordination, mentoring, and management in the emerging ‘new normal’ of work?
  • Has the global pandemic changed the way people think about their personal and professional development? What should we as leaders be doing to better understand and support how our people want to grow?

Brendan Hughes
SVP Global Manufacturing Operations
Bristol-Myers Squibb

Brendan is responsible for all of BMS Pharma and Biologics manufacturing from internal and external sources. He is based in Devens MA.

Brendan joined BMS as Head of CMC Strategy for Biologics in 2012. From 2015-2020 Brendan led MS&T for the company with responsibility for all technologies used in manufacturing including biologics, pharma products, parenterals and devices.

Before joining BMS, he led MS&T and Technical Services teams in Wyeth and Pfizer.

Brendan has worked in the US, Ireland and the UK. He started his career in the UK working for Wellcome which then became Glaxo-Wellcome and then GSK; roles included leadership positions in Quality, analytical sciences as well as project leadership. Brendan came to US in 2001 joining the Biotech Development team in Wyeth. He later joined the leadership team for the Wyeth Grange Castle biotech start-up in Ireland from 2003-2010 and returned to US in 2010 to work in Pfizer Global Manufacturing.

Brendan received his B.Sc and Ph.D in Biochemistry in Ireland and carried out post-doctoral studies in Oxford UK. He was a member of the ICH Expert Working Group which drafted the initial Quality Guidelines for biotech products in the 1990s and later for ICH Q11.

Charles L. Cooney
Robert T. Haslam Professor of Chemical Engineering, Emeritus, & Faculty Director, Emeritus Deshpande Center for Technological Innovation

Charles L. Cooney is the Robert T. Haslam (1911) Professor of Chemical and Biochemical Engineering, Emeritus in the Department of Chemical Engineering at MIT and founding Faculty Director, Emeritus of the Deshpande Center for Technological Innovation. He has been involved as founder, advisor or board member of over 25 companies and currently sits on the Boards of Directors of Codiak Bioscience, Innovent Biologics (1801.HK), Elektofi, Hovione, LayerBio, Boyd Technologies, Levitronix Technologies, and is chairman of GreenLight Bioscience. In addition, he is Trustee Emeritus of Boston Ballet, Advisor Emeritus of the Boston Symphony Orchestra and Trustee and Treasurer of the Leventhal Map and Education Center. Other interests include: high altitude mountaineering (assents of Denali, Ama Dablam, Mont Blanc, Kilimanjaro, Huascaran). and antique map collecting.

Derek Adams
Chief Operating Officer

Derek Adams is PlateletBio’s Chief Operating Officer. Derek has spent the past four years as Chief Technology and Manufacturing Officer at bluebird bio, a leading lentiviral gene therapy company, overseeing pharmaceutical sciences and quality functions: process and analytical development, vector manufacturing, patient operations, global supply chain, quality assurance and quality control. Prior to that, Derek was Senior Vice President of Chemistry, Manufacturing and Controls at Evelo Biosciences, establishing the process development function and supply chain for clinical studies. For over a decade prior to Evelo, he held senior leadership roles of increasing responsibility in process development and manufacturing at Alexion Pharmaceuticals, where he led process development, analytical sciences, global technical services and clinical supply within global operations and helped to more than double the size of the clinical manufacturing network. Derek started his manufacturing career with Merck & Co, Inc. as a Process Engineer for vaccine production technologies. He earned a Ph.D. in Chemical Engineering from the University of Minnesota and a B.S. in Chemical Engineering with High Distinction from Worcester Polytechnic Institute (WPI).

Aine Hanly
Chief Technology Officer
Vir Biotechnology

Aine Hanly, Ph.D., serves as Chief Technology Officer at Vir Biotechnology, where she is responsible for overseeing the Company’s technical operations. Her purview includes product and process development, supply chain, manufacturing, quality and CMC strategy. Her career in the biomanufacturing industry, which has spanned roles in the UK, Ireland and the US, has been dedicated to advancing innovative solutions to accelerate the delivery of medicines to patients.

Prior to joining Vir, Dr. Hanly served as the Vice President of Process Development for Amgen, accountable for clinical manufacturing and global supply of clinical trial materials. During her nearly decade-long tenure, she led teams enabling the commercialization of Amgen’s pipeline products as well as providing technical support for ongoing commercial manufacturing operations. Additionally, as site head at Amgen’s Cambridge facility, Dr. Hanly led the site’s transformation and staff growth, and together with the research and development team, greatly increased Amgen’s partnerships and presence within the local Cambridge ecosystem. She also worked for more than 10 years at Pfizer (formerly, Wyeth), where she held roles of increasing responsibility in analytical R&D, process development, quality and product supply strategy.

Dr. Hanly received her bachelor’s degree in biological chemistry and a Ph.D. in physical organic chemistry, from the University of Ulster, Northern Ireland. She completed her post-doctoral fellowship at Creighton University School of Medicine before joining the collaborative research wing at Yale University and CuraGen Corporation as lead scientist studying gene isolation and subsequent confirmation using a variety of molecular biology techniques.